UNSPSC 51152052: Cyclobenzaprine hydrochloride

This classification denotes a muscle relaxant and antidepressant agent with the molecular formula C20H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VE05JYS2P, chemically known as 10,11-dehydroamitriptyline but more generally known as cyclobenzaprine hydrochloride, which bears US NIH Compound Identifier 2895. European Medicines Agency schedules Cyclobenzaprine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13514MIG.

Most nations, for tariff and trade purposes, schedule cyclobenzaprine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, CYCLOBENZAPRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyclobenzaprine hydrochloride bears US NLM identifiers UMLS ID C0125988 and NCI Concept Code C47465. SMILES: CN(C)CCC=C1C2CCCCC2C=CC3C1CCCC3.CL.

UNSPSC 51152052 Cyclobenzaprine hydrochloride is a Commodity code for a specific muscle-relaxant pharmaceutical product, but the recent state and local opportunities tagged under this code show a significant mismatch between the code's nominal scope and the work actually being solicited. The Seminole County, Florida IFB (Solicitation Number IFB60459723LAS) seeks naloxone and drug deactivation systems rather than cyclobenzaprine, while the Texas Health and Human Services Commission RFI (HHS0017013) solicits vendor capabilities for a direct-to-manufacturer prescription program without specifying individual pharmaceutical products. State and local procurement under this code shows little relevant recent activity aligned with the code's stated pharmaceutical product.

The issuing bodies include a county health department (Seminole County) and a state health commission (Texas HHS), suggesting sporadic activity across public health and human services agencies. The Seminole County opportunity, posted June 30, 2026 with response due July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with all shipping and delivery costs included in bids; the contract carries a two-year initial term with a one-year renewal option and potential FEMA funding. The Texas RFI, posted April 3, 2026 and due the same day, gathers preliminary market intelligence on direct-to-manufacturer prescription fulfillment without committed budget ranges or formal competitive timelines. Geographic activity centers on Florida and Texas, though the sparse volume and mismatch between the code and actual solicitations suggest this Commodity code is not reliably capturing pharmaceutical procurement in state and local markets.